(0.21%) 5 110.78 points
(0.29%) 38 351 points
(0.11%) 15 945 points
(-0.38%) $83.53
(2.39%) $1.969
(-0.23%) $2 341.70
(-0.37%) $27.43
(2.72%) $947.15
(0.03%) $0.935
(-0.05%) $11.02
(-0.21%) $0.799
(1.90%) $93.62
Quarter results tomorrow
(amc 2024-04-30)
Expected move: +/- 5.00%
@ $23.70
发出时间: 27 Apr 2024 @ 03:47
回报率: 0.49%
上一信号: Apr 26 - 01:51
上一信号:
回报率: 0.87 %
Live Chart Being Loaded With Signals
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States...
Stats | |
---|---|
今日成交量 | 59 269.00 |
平均成交量 | 2.24M |
市值 | 7.02B |
EPS | $0 ( 2024-02-06 ) |
下一个收益日期 | ( $0.280 ) 2024-04-30 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 36.64 |
ATR14 | $0.306 (1.28%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-21 | Garber Alan M | Buy | 23 491 | Common Stock |
2024-03-21 | Garber Alan M | Sell | 19 205 | Common Stock |
2024-03-21 | Garber Alan M | Sell | 23 491 | Option (right to buy) |
2024-02-23 | Peterson Amy C. | Buy | 82 121 | Common Stock |
2024-02-23 | Aftab Dana | Buy | 63 350 | Common Stock |
INSIDER POWER |
---|
27.66 |
Last 94 transactions |
Buy: 3 435 845 | Sell: 2 083 268 |
音量 相关性
Exelixis Inc 相关性 - 货币/商品
Exelixis Inc 财务报表
Annual | 2023 |
营收: | $1.83B |
毛利润: | $1.76B (96.04 %) |
EPS: | $0.650 |
FY | 2023 |
营收: | $1.83B |
毛利润: | $1.76B (96.04 %) |
EPS: | $0.650 |
FY | 2022 |
营收: | $1.61B |
毛利润: | $1.55B (96.41 %) |
EPS: | $0.570 |
FY | 2021 |
营收: | $1.43B |
毛利润: | $1.38B (96.32 %) |
EPS: | $0.733 |
Financial Reports:
No articles found.
Exelixis Inc
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。